NCCM
STML

Nine Chapters Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Nine Chapters Capital Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-19,000
Closed -$224K – 1262
2015
Q2 		$224K Buy
+19,000
New +$264K 0.02% 792

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Nine Chapters Capital Management's STML Position: Q3 2015 in Review

Nine Chapters Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q3 2015, closing a stake of 19,000 shares — an estimated $224K sold.

Nine Chapters Capital Management first reported a position in STML in Q2 2015 and held it in 1 quarter. The position peaked at $224K in Q2 2015. 62 funds tracked by Wall St. Rank hold STML as of Q3 2015.

  • Nine Chapters Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 19,000 Stemline Therapeutics, Inc. shares in Q3 2015, an estimated $224K.
  • Nine Chapters Capital Management first reported a position in Stemline Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Nine Chapters Capital Management's Stemline Therapeutics, Inc. position peaked at $224K in Q2 2015.
  • 62 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2015.

Based on Nine Chapters Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.